• Text Resize A A A
  • Print Print
  • Share Share on facebook Share on twitter Share

NVAC Resolution: Surveillance – Adverse Events Following Immunization

January 22, 1996

The NVAC, in recognizing the critical importance of the collection and analysis of both passive and active surveillance information on potential adverse events and effects of childhood and adult vaccines, recommends that the Secretary of the Department of Health and Human Services seek, identify, and establish a source of stable funding for Large Linked Data Base studies, as well as other active surveillance efforts. This action is essential to the success of national vaccine safety efforts, and the Committee believes that comprehensive surveillance data will improve the communication of vaccine risk to both providers and parents.

The NVAC recognizes the tremendous effort by the Public Health Service, including the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), US Agency for International Development (USAID), and the National Vaccine Program Office (NVPO) through the Inter-Agency Group, in promoting the development of safe and effective acellular pertussis vaccines for use in infants in the United States. The NVAC especially wishes to acknowledge Dr. John LaMontagne, Dr. George Curlin, and Dr. David Klein for their leadership in the National Institute of Allergy and Infectious Diseases (NIAID)-supported efficacy trials in infants in Sweden and Italy.

Content created by National Vaccine Program Office
Content last reviewed on March 22, 2016
Back to Top